# Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)

> **NCT00863148** · PHASE2 · COMPLETED · sponsor: **Nantes University Hospital** · enrollment: 30 (actual)

## Conditions studied

- MDS
- AML
- ALL
- BAL

## Interventions

- **DRUG:** Clofarabine in combination with IV busulfan and ATG

## Key facts

- **NCT ID:** NCT00863148
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00863148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00863148, "Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00863148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*